Status: Recruiting
Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease
The EPOCA study (Evaluation of a POlypill and Colchicine for risk reduction in patients with established Atherosclerotic cardiovascular disease) will be a randomized, superiority, parallel, 2x2 factorial, multicenter clinical trial which will include at least 7713 and up to a maximum of 10797 participants with established atherosclerotic cardiovascular disease.
Participants needed: 7,713
Trial details
Phase: Phase 3Age: 45+Biological sex: AllType: InterventionalSponsor: Hospital do CoracaoUpdated: Jan 22, 2026Locations: 13
Eligibility criteria
Individuals aged ≥ 45 years AND [+3]
Pregnant or lactating women; [+19]